On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...